Results 201 to 210 of about 2,362,461 (350)

Safety of a novel oral immunotherapy approach in preschool children with single and multiple food allergies. [PDF]

Front Allergy
Barten LJC, Faber J, Kamphorst K, Philips D, Garssen J, Klok T.   +5 more
europepmc   +1 more source

Microtopography enhances intestinal drug absorption via Piezo1‐mediated tight junction modulation

BMEMat, EarlyView.
Microtopography‐driven enhancement of oral peptide drug delivery by activating Piezo1 channels significantly improves paracellular permeability and bioavailability, offering a novel approach for optimizing macromolecule absorption in pharmaceutical formulations.
Yu Hu, Nan Xu, Xin Li, Xiaowo Kang, Tieyuan Bian, Junsheng Lin, Hao Tang, Yinyin Bao, Lu Zhang, Hongyan Yuan, Mingxi Yao, Xingyu Jiang, Zhi Luo   +12 more
wiley   +1 more source

Case report: Milk oral immunotherapy for adult-onset cow's milk-induced anaphylaxis. [PDF]

Asia Pac Allergy
Jang JH, Lee S, Ye YM.
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

Dosing Reactions and Missed Doses Affect Peanut Oral Immunotherapy Outcomes. [PDF]

J Allergy Clin Immunol Pract
Olayiwola O, Mudd L, Dunaway L, Laidlaw TM, Jones SM, Fulkerson PC, Sanda S, Huffaker MF.   +7 more
europepmc   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

BMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning, Yunhan Sun, Mingyang Li, Shilu Liu, Fangjie Yi, Hongfei Wang, Ruibing Bai, Dongdong Liu, Fen Zhao, Guiqiang Zhang, Xiao Fu   +10 more
wiley   +1 more source

Successful Oral Immunotherapy (OIT) Due to Anti-IgE Protection. [PDF]

J Clin Med
Yoosefi Moridani M, Lau S, Beyer K.
europepmc   +1 more source

Synthetic Cathepsin B Sensitive Adjuvant‐Peptide Conjugates to Target Intracellular Toll‐Like Receptors 7 and 8

ChemistryEurope, EarlyView.
Cathepsin B‐sensitive peptide–adjuvant conjugates are designed, synthesized, and evaluated to deliver an antigenic peptid and an adjuvant targeting Toll‐like receptors 7 and 8 (TLR7/8) to antigen presenting cells. The adjuvant is released by cathepsin B resulting in antigen presentation and TLR mediated T cell activation.
Marjolein M. E. Isendoorn, Giulia Castello, Nico J. Meeuwenoord, Martijn Verdoes, Jeroen D. C. Codée, Ferry Ossendorp, Dmitri V. Filippov   +6 more
wiley   +1 more source

Heat-treated egg allergens show lower basophil activation: A path toward safer oral immunotherapy. [PDF]

Pediatr Allergy Immunol
Paolucci M, Breiding M, Dietrich M, Meyer JG, Duda A, Köhli A, Lang CCV, Agah S, Wuenschmann S, Eyer K, Kündig TM, Trück J, Johansen P.   +12 more
europepmc   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source